



## **2022 Targeted Therapies Patient Forum**

# **The ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC**

**Dr. Fred Hirsch (Executive Director, Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai, Professor of Medicine, Icahn School of Medicine, Associate Director, Biomarker Discovery for TCI)**

### **TRANSCRIPT**

ADAURA is a study that studied Osimertinib in early-stage disease. So far, we have talked about advanced diseases. Now we need to move what we have learned from advanced disease up to early-stage disease. Early-stage disease is still the situation where we have the best chances for a cure, not the only chances for a cure, mind you. We have, as I said, good results also with advanced disease, but we need to focus on early detection of lung cancer to achieve early-stage disease and be effective in treating early-stage disease. That is a common strategy these days. And there are patients with EGFR mutations having early-stage disease. And we can see here if you give those patients an EGFR TKI, these patients do better than those on standard care. That was a landmark study and has led to a focus on targeted therapies, also for early-stage disease.